An aptamer specific for modulating the function of intracellular transcription factor NF-κB has been developed and shows effective inhibition of NF-κB in vitro and in vivo28, 29, suppressing non-small cell lung cancer resistance to Doxorubicin30. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.